Results 191 to 200 of about 148,177 (294)

Development‐based In Vivo Bioreactor Strategy for Challenging Senescent Bone Reconstruction

Advanced Science, EarlyView.
We present a development‐based in vivo bioreactor strategy to generate rejuvenated bone grafts (vBR‐Bone) within aged hosts. By enclosing vBR‐Bone fragments within an asymmetric biomimetic periosteum, segmental femoral defects in aged mice were successfully repaired within 6 weeks. Mechanistically, the multifactors of vBR‐Bone reconstitute a remodeling
Wenchao Zhang, Kai Dai, Tong Shen, Zehua Gao, Fengying Yan, Yuke Feng, Xuanlin Wang, Shaozhen Zhang, Jing Wang, Changsheng Liu   +9 more
wiley   +1 more source

Reframing-renaming(?)-myelodysplastic syndromes/neoplasms and clonal hematopoiesis of indeterminate potential. [PDF]

Leukemia
Lee NC, Miao R, Young NS.
europepmc   +1 more source

Studying Macromolecular Composition in Cell–Cell Interfaces Using 3D Membrane Reconstitution Systems

Advanced Science, EarlyView.
A comprehensive understanding of the interactions between proteins, lipids and glycocalyx components at the immune synapse is still lacking. Here, an artificial and a semi‐artificial model contact system were established to reconstitute the cell‐cell contact in 3D. The model systems enable the examination of macromolecule enrichment or depletion at the
Franziska Ragaller, Amelie Maribel Schneider, Ellen Sjule, Renhua Sun, Xiao Han, Luca Andronico, Edward Jenkins, Michael Dustin, Adnane Achour, Erdinc Sezgin   +9 more
wiley   +1 more source

Hematopoietic organoids: Opportunities and challenges in modeling human hematopoiesis and diseases in vitro. [PDF]

Stem Cell Reports
Du L, Huang Y, Liu F.
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Hematopoietic stem cell-independent and -dependent hematopoiesis: new insights and lineage-tracing methods.

Exp Hematol
Ganuza M, Yoshimoto M.
europepmc   +1 more source

Evolution of hematopoietic stem cell potential from preterm to term neonates. [PDF]

Hemasphere
Quaranta P, Basso-Ricci L, Seffin L, Pacini G, Ronchi A, Crimi R, Fumagalli M, Pietrasanta C, Scala S.   +8 more
europepmc   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

DHX9 sustains hematopoietic stem cell function in cooperation with H3 acetylation. [PDF]

Stem Cell Reports
Shi M, Gao M, Luo H, Wang C, Hu X, Xiong Y, Chen Y, Ren X, Zhu S, Zhu H.   +9 more
europepmc   +1 more source

Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity

Advanced Science, EarlyView.
This study demonstrates that an albumin‐bound STING agonist (Nano ZSA‐51D) reprograms HSPCs to produce antitumor neutrophils with enhanced MHC I–mediated CD8+ T cell activation, thereby sensitizing tumors to α‐PD1 therapy. These findings highlight a strategy to target early hematopoiesis for shaping neutrophil fate and potentiating cancer immunotherapy.
Jinsong Tao, Hong‐Yi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Kai Sun, Wei Gao, Duxin Sun   +11 more
wiley   +1 more source